

ForPatients

by Roche

Idiopathic Pulmonary Fibrosis (IPF)

A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

Trial Status
Terminated

Trial Runs In
28 Countries

Trial Identifier
NCT04594707 2020-001429-30
WA42294

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the long-term safety, efficacy and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, administered by intravenous (IV) infusion to participants with idiopathic pulmonary fibrosis (IPF).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT04594707 2020-001429-30 WA42294
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
All

Healthy Volunteers
No
